Letters Reboxetine in depression

NICE guidance differs, so where next?

BMJ 2010; 341 doi: http://dx.doi.org/10.1136/bmj.c6484 (Published 16 November 2010) Cite this as: BMJ 2010;341:c6484
  1. Rajeev Krishnadas, clinical lecturer in psychological medicine1
  1. 1Sackler Institute of Psychobiological Research, Southern General Hospital, Glasgow G51 4TF, UK
  1. rajeev.krishnadas{at}glasgow.ac.uk

Eyding and colleagues claim that reboxetine is an ineffective and potentially harmful antidepressant, and call for the mandatory publication of trial data to exclude publication bias.1

The updated guidelines from the National Institute for Health and Clinical Excellence (NICE) suggest that strong evidence favours reboxetine over placebo in achieving a response or …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe